Structure Therapeutics (GPCR) Enterprise Value (2022 - 2026)
Structure Therapeutics (GPCR) posted quarterly Enterprise Value of -$2.6 billion for Q1 2026, down 70.55% year-over-year from -$8.8 billion in Q1 2025, and down 79.45% quarter-over-quarter from -$1.4 billion in Q4 2025.
Structure Therapeutics (GPCR) Enterprise Value (2022 - 2026) Analysis & Trends
Structure Therapeutics' Enterprise Value history runs 5 years deep, the most recent figure standing at -$2.6 billion for Q1 2026.
- In Q1 2026, Enterprise Value fell 70.55% year-over-year to -$2.6 billion; the TTM figure through Mar 2026 stood at -$2.6 billion (down 70.55% YoY), while the FY2025 annual figure was -$1.4 billion, up 9.01% from the prior year.
- Enterprise Value for Q1 2026 stood at -$2.6 billion, down from -$1.4 billion in the prior quarter.
- The five-year high for Enterprise Value was -$90.8 million in Q4 2022, with the low at -$2.6 billion in Q1 2026.
- The 5-year median for Enterprise Value is -$850.9 million (2024), against an average of -$948.3 million.
- The sharpest annual moves came in 2023 and 2025: Enterprise Value slumped 414.44% in 2023, then increased 15.17% in 2025.
- Structure Therapeutics' Enterprise Value stood at -$90.8 million in 2022, then plunged by 414.44% to -$467.3 million in 2023, then slumped by 240.1% to -$1.6 billion in 2024, then increased by 9.01% to -$1.4 billion in 2025, then tumbled by 79.45% to -$2.6 billion in 2026.
- Business Quant data shows GPCR's Enterprise Value at -$2.6 billion in Q1 2026, -$1.4 billion in Q4 2025, and -$1.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Structure Therapeutics | 11.65 Bn | 11.65 Bn | - | -2.41 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.41 Bn |
| Mar 31, 2026 | -2.60 Bn |
| Dec 31, 2025 | -1.45 Bn |
| Sep 30, 2025 | -1.50 Bn |
| Jun 30, 2025 | -786.50 Mn |
| Mar 31, 2025 | -1.52 Bn |
| Dec 31, 2024 | -1.59 Bn |
| Sep 30, 2024 | -915.29 Mn |
| Jun 30, 2024 | -927.12 Mn |
| Mar 31, 2024 | -436.45 Mn |
| Dec 31, 2023 | -467.32 Mn |
| Sep 30, 2023 | -360.19 Mn |
| Jun 30, 2023 | -403.56 Mn |
| Mar 31, 2023 | -240.86 Mn |
| Dec 31, 2022 | -90.84 Mn |